MensahGAWeiGSSorliePD, et al.
Decline in cardiovascular mortality: possible causes and implications. Circ Res2017;
120: 366–380. DOI: 10.1161/CIRCRESAHA.116.309115.
3.
SiegelRLMillerKDJemalA.Cancer statistics, 2020. CA: A Cancer Journal for Clinicians2020;
70: 7–30. DOI: 10.3322/caac.21590.
Caro-CódonJLópez FernándezTÁlvarez-OrtegaC, et al.
Cardiovascular risk factors during cancer treatment. prevalence and prognostic relevance: insights from the CARDIOTOX registry.Eur J Prev Cardiol2020.
6.
PiepoliMFHoesAWAgewallS, et al.
2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR).Eur J Prev Cardiol2016;
23: Np1–Np96. 2016/06/30. DOI: 10.1177/2047487316653709.
7.
López-SendónJÁlvarez-OrtegaCZamora AuñonP, et al.
Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry. Eur Heart J2020;
41: 1720–1729. DOI: 10.1093/eurheartj/ehaa006.
8.
TaraSCrystalSDSaroA, et al.
NCCN Guidelines insights: survivorship, version 2. 2019.J Natl Compr Canc Netw2019;
17: 784–794. DOI: 10.6004/jnccn.2019.0034.
9.
LannerstadOSternbyNHIsacssonSO, et al.
Effects of a health screening on mortality and causes of death in middle-aged men. A prospective study from 1970 to 1974 of mean in Malmö, born 1914. Scand J Soc Med1977;
5: 137–140. 1977/01/01. DOI: 10.1177/140349487700500305.
10.
MargolisJRGillumRFFeinleibM, et al.
Community surveillance for coronary heart disease: the Framingham cardiovascular disease survey: methods and preliminary results. Am J Epidemiol1974;
100: 425–436.
LancellottiPGalderisiMDonalE, et al.
Protocol update and preliminary results of EACVI/HFA Cardiac Oncology Toxicity (COT) Registry of the European Society of Cardiology. ESC Heart Fail2017;
4: 312–318. 2017/05/02. DOI: 10.1002/ehf2.12162.
13.
LapirowDLa GercheAToroC, et al. The Australia and New Zealand Cardio-Oncology Registry (ACOR): evaluation of chemotherapy-related cardiotoxicity in a national cohort of paediatric cancer patients. Intern Med J. Epub ahead of print 17 December 2019. DOI: 10.1111/imj.14719.
14.
LenihanDJFradleyMGDentS, et al.
Proceedings from the Global Cardio-Oncology Summit.The Top 10 Priorities to Actualize for CardioOncology2019;
1: 256–272. DOI: 10.1016/j.jaccao.2019.11.007.
15.
HowdenEJBigaranABeaudryR, et al.
Exercise as a diagnostic and therapeutic tool for the prevention of cardiovascular dysfunction in breast cancer patients. Eur J Prev Cardiol2019;
26: 305–315. DOI: 10.1177/2047487318811181.
16.
GilchristSCBaracAAdesPA, et al.
Cardio-oncology rehabilitation to manage cardiovascular outcomes in cancer patients and survivors: a scientific statement from the American Heart Association. Circulation2019;
139: e997–e1012. DOI: doi:10.1161/CIR.0000000000000679.